APA (7th ed.) Citation

Forster, M., Mason, J., Moleron, R., Sacco, J., Beasley, M., Reis Ferreira, M., . . . Rashid, M. (2024). 870P POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). Annals of Oncology, 35, S623. https://doi.org/10.1016/j.annonc.2024.08.931

Chicago Style (17th ed.) Citation

Forster, M.D, et al. "870P POPPY: A Phase II Trial to Assess the Efficacy and Safety Profile of Pembrolizumab in Patients of Performance Status 2 with Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC)." Annals of Oncology 35 (2024): S623. https://doi.org/10.1016/j.annonc.2024.08.931.

MLA (9th ed.) Citation

Forster, M.D, et al. "870P POPPY: A Phase II Trial to Assess the Efficacy and Safety Profile of Pembrolizumab in Patients of Performance Status 2 with Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC)." Annals of Oncology, vol. 35, 2024, p. S623, https://doi.org/10.1016/j.annonc.2024.08.931.